StockData
Evommune, Inc. logo

Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$6.88−0.14 (-1.99%)

Close on Nov 18, 2026Market cap $249.69MP/E –Yield –

Evommune net income

Net income is the profit left for shareholders after every expense, interest and tax.

Evommune's net income for the twelve months ending Sep 30, 2026 was -$113.07M. For fiscal 2025 it was -$68.87M.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$68.87M–
FY2024Dec 31, 2024-$66.81M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$30.88M–
Q2 FY2026Jun 30, 2026-$32.25M–
Q1 FY2026Mar 31, 2026-$21.67M–
Q4 FY2025Dec 31, 2025-$28.27M–
Q3 FY2025Sep 30, 2025-$12.48M–
Q2 FY2025Jun 30, 2025-$13.57M–
Q1 FY2025Mar 31, 2025-$14.56M–
Q4 FY2024Dec 31, 2024-$20.73M–
Q3 FY2024Sep 30, 2024-$15.92M–

More Evommune figures

See a number that looks wrong?